Screener
Eligibility screening
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
1 US site in TX
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.